An open randomised trial to evaluate different therapeutic strategies of combination therapy for human immunodeficiency virus (HIV-1) Infectio

Completed

• Conditions: HIV-1 infection; Infections and Infestations; Human immunodeficiency virus (HIV)

• Registration Number: ISRCTN44582462
• Lead Sponsor: Medical Research Council (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09-28
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

The participants in the trial must be HIV-1 infected, over 18 years of age, at any stage of HIV disease, but not acute symptomatic primary infection, where anti-retroviral therapy is indicated. Participants should be likely to take their first regimen for at least 6 months and be expected to adhere to the protocol.

Exclusion Criteria

1. The participants must not have received prior treatment with antiretroviral drugs or immunotherapy
2. There must be no history of peripheral neuropathy or pancreatitis
3. Individuals must not be receiving combination cytotoxic chemotherapy for cancer or parental therapy for an active opportunistic infection
4. Women should not be pregnant, breastfeeding or unwilling to use adequate contraception
5. Participants will be ineligible if biochemistry and haematology blood results from screening are outside the trial upper safety limits.

Study & Design

• Study Type: Interventional
• Study Design: Not specified